Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Study ID
NCT02497820

Study type
Interventional

Study phase
Phase 3

Study status
Not yet recruiting

Trial Acronym

CaPP3 Israel

Trial Summary

A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).

More informations

Trial Starting Date

Sep 30,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

1800